PPCB vs TT · P/E 0.0, $3.9M cap vs P/E 36, rev $21.32B
Propanc Biopharma, Inc. Common Stock (PPCB) versus Trane Technologies plc (TT) — a side-by-side from cached financials, not a winner call.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Trane Technologies plc (TT) is a building products & equipment company listed on NYSE.
PPCB does not have a complete income-statement cache yet.
Latest reported TT revenue for 2025-12-31 was $21.32B. Net income was $2.92B. Revenue was up 7.5% from 2024-12-31 to 2025-12-31. TT currently screens at market cap $104.45B and trailing P/E 36.2.
PPCB currently screens at market cap $3.9M and trailing P/E 0.0. TT currently screens at market cap $104.45B and trailing P/E 36.2.
Not investment advice. Open the PPCB and TT stock pages for the full models.
Not investment advice.